Cabergoline treatment in cats with diabetes mellitus and hypersomatotropism

DIEGO D MICELI; JORGE D GARCÍA; GUSTAVO A POMPILI; JUAN P REY AMUNATEGUI; SERGIO FERRARIS; OMAR PIGNATARO; MIRTHA GUITELMAN

JOURNAL OF FELINE MEDICINE AND SURGERY

ELSEVIER SCI LTD

Lugar: Amsterdam; Año: 2022

1098-612X

Objectives The aim of this study was to evaluate the safety and efficacy of cabergoline to control hypersomatotropism (HST) and diabetes mellitus (DM) in cats.Methods This was a prospective cohort study. Twenty-three cats with HST and concurrent DM were enrolled. Cats received a dose of 10 μg/kg cabergoline q48h PO for 6 months. Serum insulin-like growth factor 1 (IGF-1) and fructosamine concentrations, insulin dose and Insulin Resistance Index (IRI) were measured at the time of diagnosis of HST and at the start of cabergoline treatment (t0), and 3 months (t1) and 6 months (t2) during cabergoline treatment.Results A decrease and normalization of serum IGF-1 concentration was observed in 35% and 26% of cats, respectively. Median IGF-1 (t0: 1350 ng/ml [range 832?1501]; t1: 1284 ng/ml [range 365?1501]; t2: 1240 ng/ml [range 263?1501]; P = 0.016) decreased significantly. Twelve cats underwent diagnostic imaging of the pituitary area. The median pituitary height at t0 of cats that experienced an IGF-1 reduction (n = 5/12) was significantly lower compared with those that did not experience an IGF-1 reduction (n = 7/12) (3.2 mm [range 3.1?3.7] vs 6 mm [range 3.5?9.5]; P = 0.011). Median fructosamine (t0: 628 μmol/l [range 400?963]; t1: 404 μmol/l [range 249?780]; t2: 400 μmol/l [range 260?815]; P